X-linked lymphoproliferative syndrome.
Nelson DL, Terhorst C.
Clin Exp Immunol. 2000 Dec;122(3):291-5. doi: 10.1046/j.1365-2249.2000.01400.x.
X-linked lymphoproliferative syndrome.
Sullivan JL, Woda BA.
Immunodefic Rev. 1989;1(4):325-47.
X-linked lymphoproliferative syndrome: a genetic condition typified by the triad of infection, immunodeficiency and lymphoma.
Rezaei N, Mahmoudi E, Aghamohammadi A, Das R, Nichols KE.
Br J Haematol. 2011 Jan;152(1):13-30. doi: 10.1111/j.1365-2141.2010.08442.x. Epub 2010 Nov 18.
[X-linked lymphoproliferative syndrome].
Kanegane H.
Nihon Rinsho Meneki Gakkai Kaishi. 2002 Feb;25(1):129-34.
X-linked inhibitor of apoptosis protein deficiency: more than an X-linked lymphoproliferative syndrome.
Aguilar C, Latour S.
J Clin Immunol. 2015 May;35(4):331-8. doi: 10.1007/s10875-015-0141-9. Epub 2015 Mar 4.
Hemophagocytic lymphohistiocytosis secondary to X-linked lymphoproliferative syndrome type 2.
Laguna Del Estal P, Galán Gómez A, García Prieto S.
Med Clin (Barc). 2021 Aug 27;157(4):207-208. doi: 10.1016/j.medcli.2020.05.043. Epub 2020 Aug 18.
Post-Transplantation Lymphoproliferative Disorders in Adults.
Dierickx D, Habermann TM.
N Engl J Med. 2018 Feb 8;378(6):549-562. doi: 10.1056/NEJMra1702693.
The abnormal gene in X-linked lymphoproliferative syndrome.
Sullivan JL.
Curr Opin Immunol. 1999 Aug;11(4):431-4. doi: 10.1016/S0952-7915(99)80072-7.
X-Linked Lymphoproliferative Syndrome Presenting as Adult-Onset Multi-Infarct Dementia.
Blackburn PR, Lin WL, Miller DA, Lorenzo-Betancor O, Edwards ES, Zimmermann MT, Farrugia LP, Freeman WD, Soto AI, Walton RL, Klee EW, Atwal PS, Abraham RS, Billadeau DD, Ross OA, Dickson DW, Meschia JF.
J Neuropathol Exp Neurol. 2019 May 1;78(5):460-466. doi: 10.1093/jnen/nlz018.
X-linked lymphoproliferative disease.
Seemayer TA, Grierson H, Pirruccello SJ, Gross TG, Weisenburger DD, Davis J, Spiegel K, Brichacek B, Sumegi J.
Am J Dis Child. 1993 Nov;147(11):1242-5. doi: 10.1001/archpedi.1993.02160350116018.
